BEAM Beam Therapeutics
- 22.720
- +0.980+4.51%
Beam Therapeutics News
Benign Growth For Beam Therapeutics Inc. (NASDAQ:BEAM) Underpins Stock's 30% Plummet
Beam Therapeutics Inc. (NASDAQ:BEAM) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performance. Instead
Expert Ratings For Beam Therapeutics
In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:BEAM), showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary of their recent r
Wedbush: Reiterates the Beam Therapeutics (BEAM.US) rating and adjusted from better than market to better than market rating, with a target price of $57.00.
Wedbush: Reiterates the Beam Therapeutics (BEAM.US) rating and adjusted from better than market to better than market rating, with a target price of $57.00.
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics with a Outperform and maintains $57 price target.
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: RNDR). BEAM: A Bullish Bet On Crypt
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing
Amy Simon, Chief Medical Officer, on April 01, 2024, sold 23,687 shares in Beam Therapeutics (BEAM) for $734,805. Following the Form 4 filing with the SEC, Simon has control over a total of 70,060 sha
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 504.85K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 2, $Beam Therapeutics(BEAM.US)$ Officer AMY SIMON intends to sell 16,530 shares of its common stock on Apr 2, with a total market value of approximately $504.85K. AMY SIM
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Verve Drops After Pausing Enrollments in Trial for Lead Asset
Beam Therapeutics(BEAM.US) Officer Sells US$2.03 Million in Common Stock
$Beam Therapeutics(BEAM.US)$ Officer Evans John M. sold 60,000 shares of Common Stock on Mar 28, 2024 at an average price of $33.8567 for a total value of $2.03 million.Source: Announcement What is st
Here's Why We're Not Too Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 2.03 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Mar 28, with a total market value of approximately $2.03 million.
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
In the last three months, 4 analysts have published ratings on Beam Therapeutics (NASDAQ:BEAM), offering a diverse range of perspectives from bullish to bearish.The table below offers a condensed view
Beam Therapeutics Is Maintained at Outperform by BMO Capital
Beam Therapeutics Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Outperform on Beam Therapeutics, Maintains $57 Price Target
BMO Capital analyst Kostas Biliouris maintains Beam Therapeutics with a Outperform and maintains $57 price target.
Analysis
Price Target
No Data
